Published in Int J Mol Sci on June 04, 2013
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol (2015) 1.01
Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. Elife (2017) 0.75
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
The androgen axis in recurrent prostate cancer. Clin Cancer Res (2004) 6.67
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol (1993) 6.55
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun (1990) 3.79
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res (2001) 3.37
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer (1999) 2.34
Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem (2012) 2.25
Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem (1996) 2.15
Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem (1999) 1.87
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol (1993) 1.73
Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol (2005) 1.67
In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res (2009) 1.66
Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density. Eur J Cancer (2003) 1.66
Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res (2006) 1.59
Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther (2005) 1.53
Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol (2001) 1.35
Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol (2006) 1.32
Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res (2006) 1.22
Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate (2005) 1.21
Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int (2005) 1.19
Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer (1999) 1.15
Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. Cell Signal (2010) 1.15
Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis (2002) 1.11
Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol (1998) 1.10
New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell Biol (2012) 1.07
Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate (2004) 1.06
SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS One (2007) 1.03
Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology (2008) 0.99
Potential clinical applications of siRNA technique: benefits and limitations. Eur J Clin Invest (2010) 0.97
Tumor reversion: protein kinase A isozyme switching. Ann N Y Acad Sci (2005) 0.95
Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther (2002) 0.95
Androgens transduce the G alphas-mediated activation of protein kinase A in prostate cells. Cancer Res (2008) 0.95
Molecular pathways in the progression of hormone-independent and metastatic prostate cancer. Curr Cancer Drug Targets (2010) 0.92
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer. Curr Treat Options Oncol (2012) 0.90
Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Res (2004) 0.87
Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A. Int J Cancer (2010) 0.84
Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model. Urol Int (2000) 0.83
PKA knockdown enhances cell killing in response to radiation and androgen deprivation. Int J Cancer (2010) 0.83
Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy. Clin Cancer Res (2003) 0.83
Biochemical characterization of extracellular cAMP-dependent protein kinase as a tumor marker. Biochem Biophys Res Commun (2000) 0.82
Serial tumour blood-flow measurements in androgen-dependent and -independent Shionogi tumour models. BJU Int (2005) 0.80
Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: results from a 10-year cohort analysis. Int J Radiat Oncol Biol Phys (2003) 0.79
Androgen receptor antagonists: a patent review (2008-2011). Expert Opin Ther Pat (2012) 0.77
Endothelial cells support the growth of prostate tissue in vivo. Prostate (2008) 0.77
Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum. Med Oncol (2011) 0.76
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J Exp Med (2005) 2.83
Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int (2008) 2.60
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol (2010) 2.47
Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc Natl Acad Sci U S A (2009) 2.33
Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol (2008) 2.32
Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics (2011) 2.24
Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology (2007) 1.69
Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate (2005) 1.68
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol (2008) 1.68
Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase. J Biol Chem (2002) 1.67
Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol (2005) 1.67
Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients. Am J Hum Genet (2010) 1.67
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res (2005) 1.62
Safer transurethral resection of the prostate: coagulating intermittent cutting reduces hemostatic complications. J Urol (2004) 1.54
Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol (2012) 1.48
Different types of atrophy in the prostate with and without adenocarcinoma. Eur Urol (2006) 1.48
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology (2003) 1.46
Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res (2004) 1.46
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol (2004) 1.44
Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of toll-like receptor 2. J Biol Chem (2002) 1.44
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol (2003) 1.40
hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Res (2006) 1.33
The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. J Exp Ther Oncol (2004) 1.32
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer (2008) 1.30
Plexin-B1 mutations in prostate cancer. Proc Natl Acad Sci U S A (2007) 1.28
Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice. J Immunol (2009) 1.27
The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. J Mol Med (Berl) (2012) 1.23
Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol (2006) 1.21
Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol Ther (2011) 1.21
Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. Mol Endocrinol (2007) 1.20
Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours. J Steroid Biochem Mol Biol (2006) 1.19
The Molecular Chaperone GRP78/BiP in the Development of Chemoresistance: Mechanism and Possible Treatment. Front Pharmacol (2013) 1.18
Stimulated emission depletion-based raster image correlation spectroscopy reveals biomolecular dynamics in live cells. Nat Commun (2013) 1.18
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging (2015) 1.18
Cuticle differentiation during Drosophila embryogenesis. Arthropod Struct Dev (2006) 1.17
Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer (2010) 1.16
The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab (2008) 1.15
The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol (2002) 1.15
Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis (2008) 1.13
Small G-protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis. Prostate (2005) 1.12
The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate (2010) 1.10
Long-term follow up of renal anastomosing hemangioma mimicking renal angiosarcoma. Int J Urol (2014) 1.09
Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res (2009) 1.09
Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res (2009) 1.09
Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25 ng/ml or greater and 4.00 ng/ml or less. J Urol (2010) 1.07
The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor. Mol Cell Biol (2003) 1.07
Dabigatran pharmacokinetics--implications for treatment. Am J Kidney Dis (2013) 1.07
Androgen receptors in prostate cancer. J Urol (2003) 1.07
Glucocorticoids synergize with IL-1beta to induce TLR2 expression via MAP Kinase Phosphatase-1-dependent dual Inhibition of MAPK JNK and p38 in epithelial cells. BMC Mol Biol (2004) 1.07
Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate (2004) 1.06
Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway. Carcinogenesis (2012) 1.06
Real-time sonoelastography for the evaluation of testicular lesions. Radiology (2012) 1.05
The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer. J Urol (2006) 1.05
Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res (2005) 1.04
Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis (2009) 1.03
Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer. Mol Cancer (2009) 1.02
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am J Pathol (2012) 1.02
Molecular effects of the isoflavonoid genistein in prostate cancer. Clin Prostate Cancer (2005) 1.01
Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker. J Proteome Res (2010) 1.00
Light-inducible and clock-controlled expression of MAP kinase phosphatase 1 in mouse central pacemaker neurons. J Biol Rhythms (2007) 1.00
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol (2011) 1.00
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol (2011) 1.00
Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL. BJU Int (2008) 1.00
Development of a multiplexed urine assay for prostate cancer diagnosis. Clin Chem (2008) 0.99
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid Biochem Mol Biol (2013) 0.99
Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility. Endocr Relat Cancer (2009) 0.99
Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate (2003) 0.99
The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol (2005) 0.98
Cross-talk between the p38alpha and JNK MAPK pathways mediated by MAP kinase phosphatase-1 determines cellular sensitivity to UV radiation. J Biol Chem (2010) 0.97